Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Surgery Partners Q3 2025 Earnings Call - Navigating Mixed Volume Trends Amid Strategic Portfolio Optimization
Surgery Partners reported a solid third quarter with net revenues of $821.5 million, up 6.6% year-over-year, and adjusted EBITDA of $136.4 million, up 6.1%, driven by sustained organic growth in ortho...
- Surgery Partners Q3 2025 net revenue reached $821.5 million, up 6.6% year-over-year, with adjusted EBITDA of $136.4 million, up 6.1%.
- Same-facility revenue increased 6.3%, driven by 3.4% same-facility case growth and 2.8% rate growth; total surgical cases grew 2.1%.
- Growth led by GI and musculoskeletal (MSK) procedures, especially continued strength in orthopedics with ASC total joint surgeries up 16% for the quarter and 23% year-to-date.
- +7 more takeaways
Pagaya Q3 2025 Earnings Call - Record Network Volume and Product-Driven Growth in B2B Consumer Lending
Pagaya's Q3 2025 earnings reveal robust and diversified growth within its B2B consumer lending platform, characterized by a record quarterly network volume of $2.8 billion and GAAP net income profitab...
- Pagaya reached a record quarterly network volume of $2.8 billion in Q3 2025, up 19% year-over-year.
- The company achieved GAAP net income profitability for the third consecutive quarter, improving from a prior year loss.
- Fee revenue less production costs (FRLPC) increased 39% to $139 million, representing 5% of network volume, signaling strong monetization.
- +12 more takeaways
eToro Q3 2025 Earnings Call - AI and Crypto Innovation Drive 28% Revenue Growth and Record Assets
eToro reported a robust Q3 2025 with net contribution up 28% year-over-year to $215 million and adjusted EBITDA rising 43% to $78 million, hitting a solid 36% margin. The company is aggressively advan...
- Reported 28% year-over-year growth in net contribution to $215 million and 43% rise in adjusted EBITDA to $78 million with a 36% margin.
- Assets under administration reached an all-time high of $20.8 billion, a 76% increase year-over-year driven by new deposits and strong investment returns.
- Funded accounts grew 16% year-over-year to 3.73 million, with double-digit organic growth and improved retention.
- +13 more takeaways
Wave Life Sciences Q3 2025 Earnings Call - Robust Clinical Progress in RNAi Pipeline with Exciting Obesity and RNA Editing Data
Wave Life Sciences reported significant advancements in its RNAi and RNA editing programs during the Q3 2025 earnings call. Their lead RNAi candidate, WVE-007, demonstrated potent, dose-dependent and ...
- Wave Life announced robust and dose-dependent activin E reductions with their RNAi candidate WVE-007, exceeding preclinical efficacy thresholds linked to meaningful fat loss and sustained metabolic benefits.
- The ENLIGHTEN clinical trial has enrolled over 70 participants with doses up to 600 mg, showing good safety and approval to escalate further by the data monitoring committee.
- Sustained activin E suppression was observed up to six months post single dose at lowest cohort, supporting the potential for once or twice yearly subcutaneous dosing.
- +12 more takeaways
ARS Pharmaceuticals Q3 2025 Earnings Call - Neffy Revenue Soars 2.5x Amid Strategic Commercial Innovations
ARS Pharmaceuticals hit a pivotal inflection point in Q3 2025, with U.S. net product revenue for its flagship nasal epinephrine spray, Neffy, climbing 2.5-fold quarter-over-quarter to $31.3 million, s...
- Neffy’s U.S. net product revenue hit $31.3 million in Q3 2025, a 2.5x increase from Q2, beating analyst consensus.
- Growth driven by strong new patient starts and rising demand, with surveys indicating durable utilization and refill behavior.
- Temporary market share growth pause in late Q3 due to back-to-school seasonality and physician appointment time constraints.
- +12 more takeaways
Organon Q3 2025 Earnings Call - Navigating Nexplanon Headwinds and Strategic Portfolio Moves Amidst Leadership Transition
Organon reported Q3 2025 revenues of $1.6 billion with adjusted EBITDA of $518 million, reflecting a 32.3% margin, but faces continued challenges primarily from adverse U.S. policy impacts on Nexplano...
- Organon reported Q3 2025 revenue of $1.6 billion and adjusted EBITDA of $518 million with a 32.3% margin, demonstrating operational resilience despite some headwinds.
- An internal board investigation revealed improper U.S. Nexplanon wholesaler sales practices involving sales pull-forwards late in quarters, with limited financial impact and no need for restatements.
- Sales practices impacting Nexplanon have ceased; remediation includes enhanced controls, personnel changes, additional training, and new procedures to prevent recurrence.
- +12 more takeaways
Outdoor Holding Company Q2 2026 Earnings Call - Cost Cuts and Market Share Gains Drive Profitability
Outdoor Holding Company returned to regular earnings calls following regulatory delays, reporting a steady Q2 with net sales near $12 million, flat year over year but outpacing general firearm market ...
- Outdoor Holding Company resumed quarterly earnings calls after resolving regulatory compliance issues, restoring Nasdaq compliance.
- Q2 net sales roughly $12 million, flat year-over-year, outperforming a 5% industry decline in firearm sales (adjusted NICS data).
- Gross margin improved slightly to 87.1%, supported by a higher take rate of 6.34%.
- +9 more takeaways
Immunovant Q2 2025 Earnings Call - Breakthrough Phase 3 Data in Dermatomyositis and Groundbreaking Graves' Disease Remission Results Propel Pipeline
Immunovant's Q2 2025 earnings call unfolded as a moment of quiet in tone but not in substance, as CEO Matt Gline highlighted transformative phase 3 readouts for BREPO in dermatomyositis (DM) and durab...
- Immunovant delivered positive phase 3 results with BREPO in dermatomyositis, hitting all 10 ranked endpoints and showing rapid, deep, and meaningful clinical responses.
- NDA submission for BREPO is on track for H1 2026, positioning it as the first novel oral treatment for DM, addressing a population largely reliant on steroids and off-label therapies.
- Durable remission data from the batoclimab Graves’ disease trial demonstrated sustained disease-modifying effects with 17 of 21 patients remaining responders six months drug-free.
- +7 more takeaways
Village Farms International Q3 2025 Earnings Call - Record Profitability Validates Strategic Growth and Global Expansion
Village Farms International reported a stellar Q3 2025, hitting numerous records that affirm its strategic pivot toward high-margin cannabis markets and global expansion. Consolidated net sales jumped...
- Village Farms posted 21% year-over-year consolidated net sales growth, reaching $66.7 million in Q3 2025.
- Net income from continuing operations rose to $10.8 million or $0.09 per share, improving nearly 10% sequentially from the prior quarter.
- Adjusted EBITDA from continuing operations reached a record $20.7 million with a robust 31% margin, more than tripling last year’s margin.
- +10 more takeaways
Kamada Limited Q3 2025 Earnings Call - Robust Profitable Growth and Strategic Momentum Across Product Portfolio and Plasma Operations
Kamada Limited reported solid third quarter and nine months revenue growth, driven by an 11% year-over-year increase in total revenues to $135.8 million and a 35% surge in adjusted EBITDA to $34.2 mil...
- Kamada reported third quarter revenues of $47 million, a 13% increase over Q3 2024, and $135.8 million for the first nine months of 2025, up 11% year-over-year.
- Adjusted EBITDA rose 35% year-over-year to $34.2 million for nine months, yielding a 25% margin, with a 34% increase in Q3 alone.
- The company reaffirmed full-year 2025 guidance: $178 million-$182 million in revenues and $40 million-$44 million in adjusted EBITDA, projecting double-digit growth over 2024.
- +7 more takeaways